Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Zofran

(Ondansetron)

 

Indications:

 

  • Nausea/Vomiting

 

Side Effects:

 

  • Extra-pyramidal reaction (rare)

 

Contraindications:

 

Adult Dose:

 

  • 4 mg slow IV/IM (over 2 min); may repeat once to a maximum of 8 mg
  • 4 mg ODT

 

Pediatric Dose:

 

  • 8 kg to 15 kg:
    • 2 mg slow administration IV/IM
  •  ≥16 kg:
    •  4 mg IV/IM (over 2 minutes)

 

ODT Zofran (Ondansetron) 4 mg can be given to a previously healthy child > 6 months of age